Tue Sep 17 07:16:49 UTC 2024: ## DURECT or Agile Therapeutics: Which Medical Stock is a Better Bet?

**MarketBeat News** has compared two small-cap medical companies, DURECT (DRRX) and Agile Therapeutics (AGRX), to determine which offers a more promising investment opportunity.

The analysis considered factors such as profitability, dividends, institutional ownership, valuation, earnings, risk, and analyst recommendations.

**Key Findings:**

* **Financials:** Agile Therapeutics boasts higher revenue and earnings than DURECT. However, DURECT trades at a lower price-to-earnings ratio, suggesting it’s currently more affordable.
* **Institutional Ownership:** DURECT holds a stronger institutional ownership with 28% of its shares owned by institutions compared to Agile Therapeutics’ 10.9%. This suggests a greater confidence in DURECT’s long-term growth potential.
* **Risk:** DURECT’s beta of 1.14 indicates a 14% higher volatility than the S&P 500, whereas Agile Therapeutics’ beta of 1.58 suggests a significantly higher 58% volatility.
* **Overall:** DURECT outperforms Agile Therapeutics on 8 out of 14 factors analyzed, suggesting a stronger overall investment proposition.

**Company Profiles:**

**DURECT Corporation** focuses on developing medicines based on its epigenetic regulator program. Its lead product, larsucosterol, is in clinical trials for treating liver diseases. DURECT also offers products for pain management and attention deficit hyperactivity disorder.

**Agile Therapeutics, Inc.** specializes in women’s healthcare, specifically contraceptive products. Its primary product, Twirla, is a weekly prescription contraceptive patch. The company is also developing a pipeline of additional contraceptive products.

**Conclusion:**

While both companies operate within the medical field, DURECT appears to be a stronger investment based on its financial performance, institutional ownership, and lower risk profile. However, investors should conduct further research and consult with a financial advisor before making any investment decisions.

**Disclaimer:** This article is for informational purposes only and is not intended as investment advice.

Read More